BioSpace News Archive

Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in multiple presentations at the World Orphan Drug Congress, taking place May 23-25, 2023.

Poseida Therapeutics, Inc. today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.

IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.

Seelos Therapeutics, Inc. today announced that it will participate in two upcoming healthcare conferences.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo ® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases.

Freenome announced it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.

Aethlon Medical, Inc. announced that it has received Ethics Review Board approval from the Maulana Azad Medical College, for a second site for its ongoing clinical trial of Aethlon’s Hemopurifier® to treat severe COVID-19 in India.

Enveric Biosciences, Inc. has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.

Thermo Fisher Scientific to Present at Bernstein 39th Annual Strategic Decisions Conference on May 31st , 2023.

Yaral Pharma Inc. today announced its expanding partnership with EVERSANA ® , a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S.